Home Newsfeeds Pfizer And BioNTech Begin Phase 1/2 Trial Of First-In-Class mRNA-Based Shingles Vaccine Program

News

Pfizer And BioNTech Begin Phase 1/2 Trial Of First-In-Class mRNA-Based Shingles Vaccine Program

https://investors.biontech.de/de/news-releases/news-release-details/pfizer-und-biontech-beginnen-phase-12-studie-mit-erstem-mrna

byCharles Gross

February 10, 2023

1 minute read

https://investors.biontech.de/de/news-releases/news-release-details/pfizer-und-biontech-beginnen-phase-12-studie-mit-erstem-mrna

Psychedelics Headlines: Magic Mushrooms For Sexual Wellbeing, The DEA’s Stance, The Therapist’s Role & More

By Lara Goldstein

January 8, 3:33 PM

Welcome to Benzinga's weekly psychedelics news roundup. We have pulled together several must-read news items from the last week of December 2023 and the first of January 2024.

OPTHF

Top 5 Materials Stocks That Are Preparing To Pump In October

By Lisa Levin

October 11, 8:03 AM

The most oversold stocks in the materials sector presents an opportunity to buy into undervalued companies.

News

Vista Outdoor Testifies Before Congress On Slate Of Recreation Bills

By Happy Mohamed

March 28, 4:07 PM

The company is joining other industry stakeholders to ensure that all Americans have access, opportunity, and equipment to experience the outdoors. ANOKA, Minn., March 28, 2023 /PRNewswire/ -- Vista Outdoor

VSTO

Waterstone Financial Q3 EPS $0.25 Down From $0.79 YoY

By Benzinga Newsdesk

October 26, 4:03 PM

Waterstone Financial (NASDAQ:WSBF) reported quarterly earnings of $0.25 per share. This is a 68.35 percent decrease over earnings of $0.79 per share from the same period last year.

WSBF

Pfizer And BioNTech Begin Phase 1/2 Trial Of First-In-Class mRNA-Based Shingles Vaccine Program

Related Posts

Psychedelics Headlines: Magic Mushrooms For Sexual Wellbeing, The DEA’s Stance, The Therapist’s Role & More

Top 5 Materials Stocks That Are Preparing To Pump In October

Vista Outdoor Testifies Before Congress On Slate Of Recreation Bills

Waterstone Financial Q3 EPS $0.25 Down From $0.79 YoY